A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-negative Metastatic Breast Cancer
Interventions: DRUG: DAN-222|DRUG: Niraparib
Sponsor: Dantari, Inc.